Logo

Myovant's Orgovyx (relugolix) Receives the US FDA's Approval as the First Oral GnRH Receptor Antagonist for Advanced Prostate Cancer

Share this

Myovant's Orgovyx (relugolix) Receives the US FDA's Approval as the First Oral GnRH Receptor Antagonist for Advanced Prostate Cancer

Shots:

  • The approval is based on a P-III HERO study assessing Relugolix (360mg loading dose followed by 120mg- qd) vs leuprolide acetate (3mos. depot injection) in patients with advanced prostate cancer. The therapy is expected to be available in Jan’2021
  • Results: met its 1EPs- sustained testosterone suppression to castrate levels (< 50 ng/dL) @48wks. (96.7% vs 88.8%).
  • 2EPs include @day4 & 15 suppression of testosterone to castrate levels (56% & 99% vs 0% & 12%); profound suppression of testosterone (< 20 ng/dL) @day15 (78% vs 1%); reduction in PSA by 65% @day15 and by 83% @day 29

 ­ Ref: GlobeNewswire | Image: Myovant

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions